Filing Flows › Corcept Therapeutics (CORT) › Guidance history
Corcept Therapeutics (CORT) guidance history: what it guided and what it reported
Corcept Therapeutics gave guidance in 12 earnings releases on file since Feb 15, 2024. Of 2 guided periods since reported, it met or beat its own guidance once (50%). Revenue: 1 of 2, on average -4.8% against the guided midpoint. Its releases raised guidance 5 times and lowered it 0 times.
Revenue
Met or beat 1 of 2 periods (0 above, 1 within, 1 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $900M–$1.0B (Feb 24, 2026) → raised $950M–$1.1B (Apr 30, 2026) → raised $1.1B–$1.2B (Jul 29, 2026) → reaffirmed $1.1B–$1.2B (Nov 3, 2026) | — | to be reported | — |
| FY2025 | $900M–$950M (Feb 26, 2025) → reaffirmed $900M–$950M (May 5, 2025) → lowered $850M–$900M (Jul 31, 2025) → lowered $800M–$850M (Nov 4, 2025) | $761M | below the range | -7.7% |
| FY2024 | $600M–$630M (Feb 15, 2024) → raised $620M–$650M (May 1, 2024) → raised $640M–$670M (Jul 29, 2024) → raised $675M–$700M (Oct 30, 2024) | $675M | within the range | -1.8% |
Net income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2024 | $31.4M (Feb 15, 2024) | — | — | — |
The latest quarter
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
Does Corcept Therapeutics beat its guidance?
Corcept Therapeutics gave guidance in 12 earnings releases on file since Feb 15, 2024. Of 2 guided periods since reported, it met or beat its own guidance once (50%). Revenue: 1 of 2, on average -4.8% against the guided midpoint.
How often does Corcept Therapeutics raise guidance?
Its earnings releases raised guidance 5 times and lowered it 0 times since Feb 15, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.